Background Community pharmacies are now commissioned nationally in England to provide a seasonal influenza vaccination service.
Introduction
The purpose of the seasonal influenza programme in England is to protect those who are most at risk of morbidity and mortality if they were infected. 1 It has traditionally been delivered in the main by General Practitioners (GPs). Nationally the uptake has failed to reach the 75% target for those aged under 65 years in a clinical risk group, 2 identified in accordance with the criteria given by the UK Department of Health. 1 There had been a gradual increase in England in commissioning community pharmacies to help increase uptake. 3 In 2015, NHS England agreed for pharmacies nationwide to provide influenza vaccination to adults in an at-risk group and re-commissioned it for 2016-17. 4 Community pharmacies are well established providers of seasonal influenza vaccination in the USA. 5 Immunization services can be provided safely through this route. 6 User satisfaction is high due to additional outlets and extended hours, 7, 8, 9, 10, 11 which can complement services offered by traditional providers. 12 A recent evaluation of the London pharmacy service indicated no significant change in the uptake of vaccination in any of the risk groups while suggesting a substantial loss of data. 13 In response to the need to improve vaccine uptake, a pharmacy-based vaccination service was commissioned for the 2014/15 flu season by the NHS England (NHSE) regional team for Birmingham, Solihull and Black Country. This covered an eligible population of~680 785 (over 65s and 18-64 years old in a risk group) and seven Clinical Gurpreet Kaur Rai, Consultant in Public Health, Defence Public Health Unit Annette Wood, Consultant in Public Health Commissioning Groups (CCGs) which are NHS organizations responsible for commissioning healthcare for their responsible population. Immunization programmes are, however, not commissioned by CCGs but by NHSE and monitored by the Screening and Immunization teams (SITs) embedded in NHSE. The aim of this study is to assess whether the service was effective in achieving an increased influenza vaccination uptake, by evaluating the measures undertaken by the commissioners for setting it up. The Donabedian model was used. No other studies using the Donabedian model to evaluate a vaccination service were identified.
Methods
The Donabedian Structure-Process-Outcome (SPO) model was applied. The model is flexible enough to apply to various situations and is widely used in healthcare.
14 It provided a framework to enable the analysis of the underlying mechanisms that may have contributed to vaccination uptake. The 'Structure' examined how facilities were set up to deliver a vaccination service, including information management systems and health promotion. The 'Process' focused on the scrutiny of the activities undertaken by the commissioners to monitor the service, address arising issues, engage with providers and ensure data recording. The 'Outcome' examined the influence of the vaccination service on uptake rates and patient experience.
Data sources

PharmOutcomes and ImmForm
PharmOutcomes was the web based data recording system used by the community pharmacies. Responses from the patient satisfaction survey were also recorded on PharmOutcomes. ImmForm is the national data capturing system used by GPs to record all influenza vaccination activity. GPs were expected to update patient records with the notifications received from pharmacies, to be included in ImmForm.
Pharmacist surveys A survey questionnaire was sent to all participating pharmacists at the end of the third month of the service, to get the provider experience of the setting up of the service. The response rate was 34% (127 pharmacies). Non-active pharmacies were also contacted about the reasons for not participating despite sign up.
Pharmacy audit visits
Audit visits were made to 30 (10%) of the participating pharmacies to assess their compliance with the Service Level Agreement (SLA). Pharmacies were chosen using criteria to include high and low performing pharmacies, those with complaints from GP practices and those with median uptake rates.
Project group records
A project group comprising of members from the SIT and Local Pharmaceuticals Committee (LPCs) representatives developed the SLA and the Patient Group Directive which provided the legal mechanism and written instructions for the administration of vaccinations by the pharmacists. The project group liaised with other agencies as needed. Regular planning and monitoring meetings were held. Queries and complaints were received via email, mainly from Local Medical Committees (LMCs), GPs and Practice nurses.
Mapping
Maps were developed by the Knowledge and Information team, Public Health England, to understand the distribution of participating pharmacies and those using the pharmacies.
Data analysis
All data analysis was carried out using Excel. Data available to commissioners had patient identifiables removed. Electronic data was stored on a secure drive accessible only to the SIT. Paper returns of surveys and audit forms were secured in a locked cupboard.
Results
Structure
Assessment of this element was informed by evidence from Project group planning records, PharmOutcomes and Mapping.
Pharmacy sign up Participation in the service was open to all community pharmacies in the area. A total of 376 out of 652 pharmacies (57.7%) were approved to provide the service, following submission of a signed SLA to the commissioners. Pharmacies made their own arrangements for training, ensuring sufficient supply of essentials including vaccine stock, adrenaline and sharps collection.
Pharmacy locations
Mapping showed that there were gaps where no community pharmacy had signed up for the service. These gaps were further increased due to some of the signed up pharmacies not being able to vaccinate ( Figure 1 ). Some gaps were due to the distribution of populations, e.g. Solihull has large rural areas in the south and east with a sparse population distribution.
Based on 11 of the most active pharmacies, the average straight line distance travelled by a patient to the pharmacy was 2.2 km and the maximum was 31 km (Figure 2 ). Most patients accessed a pharmacy near to their home. Seven of these pharmacies belonged to two large chain pharmacies which constituted 37% of all active pharmacies (115/315).
Service promotion and engagement with stakeholders
Two flu posters per practice were distributed by the commissioners to pharmacies via the LPCs. These were not received and displayed by all pharmacies. There was no other coordinated promotion of the service. Individual pharmacies were not part of the Planning group. GPs, LMCs, Directors of Public Health and CCGs were informed via email of plans for the service. These stakeholders were not invited to the planning meetings.
Information management
PharmOutcomes provided real-time data to monitor the vaccine uptake by pharmacy, GP, CCG and risk groups. It sent instant electronic notifications to GP practices (patients reported their GP) where a valid 'NHS.net' email was available, along with generating invoices and sending messages to the pharmacists. In the absence of a secure email address, the pharmacist was prompted to print and send notification by alternative means.
Process
Assessment of Process was informed by evidence from PharmOutcomes, ImmForm, Project Group Planning records, Pharmacy Audit visits and Pharmacist surveys.
Monitoring activity
Uptake figures were shared with stakeholders on a fortnightly basis and detailed monthly reports followed. There were no vaccination targets for pharmacies. LPCs encouraged increasing vaccination numbers via messages in their newsletter. Overall, 61 pharmacies signed up for the programme but did not vaccinate. Reasons for inactivity included short lead time for training and set up, and worry 
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about upsetting the local GPs. Delays in sending notifications were monitored and breach notices issued to those pharmacies. The majority (90%) of the vaccination notifications were sent within the specified time period of the next working day.
Issues arising
The main complaints from GP practices were about ineligible patients being vaccinated or being notified of patients not on their register. Investigations did not confirm any ineligible patients vaccinated in a pharmacy. PharmOutcomes was modified to record a patient's phone number so a pharmacist could contact the patient to check accuracy of GP practice. Eligibility of patients was modified so that a pharmacist was not to encourage vaccination if the patient intended on getting vaccinated at their GP practice. This led to confusion when patients chose to ask for vaccination by the pharmacist despite already having a booking with the GP.
Lack of engagement by commissioners with stakeholders in the planning stage was criticized and concerns about the negative impact of pharmacy provision on GP uptake and vaccine stock raised. At the end of the flu season, there were no reports of left over vaccine stock and associated financial loss. Pharmacy activity was deemed as a missed opportunity for other health checks for those aged 65 years and over and felt to be a shift of practice activity, rather than accessing new patients. Commissioners met with two LMCs and CCG representatives to discuss concerns and assure that the pharmacy service was complementary and not a replacement of GP provision. Meetings were also held with all the CCGs at the end of the service to discuss any outstanding concerns and partnership working for the next flu season.
Assessing suitability of facilities
Findings from a small sample of audited pharmacies assured the commissioners that the premises were set up in compliance with the SLA, with areas of improvements identified as infection prevention and control compliant flooring and furniture, and availability of essential Standard Operating Procedures on site. 
Communication with providers
Direct communication between commissioners and the pharmacists, using emails and PharmOutcomes, was felt to be better (83.5% stated good or very good) compared to communication via the LPCs before the start of the service (70.1% stated good or very good). In response to how things could be run differently, pharmacists suggested starting preparations and the service early, wider promotion of the service and improved communication with the GPs.
Data transfer from pharmacy to GP practice
The Other Health Care Provider (OHCP) category on the ImmForm system should include all pharmacy activity (and that by non-pharmacy providers, e.g. hospital, occupational health). OHCP data is not differentiated by providers to ascertain this. It relies on transfer of data from pharmacies and input by the Practice staff. For most CCGs, the final OHCP figures were higher than the pharmacy figures (Table 1) .
Outcome
Data from PharmOutcomes and ImmForm informs the Outcome of the evaluation.
Uptake rates A total of 8743 vaccinations were administered, of which 4938 (56.5%) were to those aged 65 years and over, 3574 (40.9%) to those at risk aged 18-64 years and 231 (2.6%) to those registered as a carer. A total of 689 (7.9%) vaccines were administered to new patients (never been vaccinated, not been vaccinated for at least 2 years and those who previously had the vaccination privately). Two large chain pharmacies (37% of all active pharmacies) delivered 3944 (45%) vaccines.
Compared to the previous year, overall there were a larger number of influenza vaccines given in 2014/15 (Table 2) . However, because the eligible cohort also increased in size, there was no increase in uptake compared to the previous year. In fact a slight reduction was seen, especially in the 18-64 years group.
Patient satisfaction
At 93.7% (8189), the response rate was high. There was high level of satisfaction with the administration of the vaccine by a pharmacist (95.8% stated vaccine administered as well as a GP or nurse). Almost all of the respondents (99.6%) stated they would be willing to use the service in the future. The main reason cited for choosing a pharmacy was convenience (78.3%) as no appointment was needed, convenient opening hours and a location close to shops or work.
Discussion
Donabedian's triad model states that structure, process and outcome must be studied in conjunction to get the most credible and complete information. 15 An evaluation of the community pharmacy service identified opportunities to improve various aspects of the Structure and Process, which could potentially lead to improved Outcomes.
Main findings
The main purpose of the community pharmacy influenza vaccination service was to increase the uptake rates in the target groups. Despite a large number of patients being 
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vaccinated, there was no increase in the uptake. Worry about ruining relationship with GPs was reported as discouraging some pharmacies from vaccinating. GPs complained of lack of engagement and lost healthcare opportunities, especially for those aged 65 years and over. Promotional activity was very limited.
What is already known on this topic
In line with previous studies, we found that the service was popular with patients. 7, 8, 9, 10 Convenience and accessibility were influential factors which have previously been identified as a reason to get vaccinated privately. 16 A survey carried out amongst physicians in the US identified concerns about records transfer and time and effort needed as barriers to collaboration. 17 Support for a pharmacy initiative is much higher amongst pharmacists than GPs. 13 With the nationwide pharmacy programme, GP discontent and concerns about wasted vaccine stock have been raised. 18 With increased numbers of pharmacies providing vaccinations and increased patient choice, increased pharmacy activity is likely to be seen. Concerns of wasted appointments and staff time, if the patients due to attend the practice are vaccinated at a pharmacy, would require further investigation. Prior to the national roll out, different areas chose different eligible groups, based on local need. 7, 8, 9, 10 With a nationwide pharmacy programme, the scope for local negotiations around eligible groups based on local need, local partnership working between GPs and pharmacies involving clear agreements on eligibility criteria and signposting mechanisms is limited.
What this study adds
The proportion of new patients vaccinated in the service was 7.9%, which was lower than that seen in Sheffield 7 (8.3%), Isle of Wight 10 (8.2%) and Cumbria 8 (11.8%), though the definition of 'new patients' and eligible groups vary. The low number of new patients suggests that the service had replaced vaccination providers rather than access new patients. The limited impact on improving uptake rates and reaching new patients, at least in part, could have been due to a lack of promotion of the service. There were no plans for signposting patients, especially 18-64 years at risk, the group with consistently low uptake rates. 2 The local geography is mostly urban and there was a good distribution of pharmacies across the area. However, there were gaps where either pharmacies had not signed up or had not been able to deliver despite participating. Patients appeared to mostly use pharmacies close to home. These findings are based on a very small sample of 11 of the most active pharmacies, all located in an urban location. A recent study suggested that 84.8% of the population in England lives within a 20 min walk of GP premises, whereas 89.2% of the population lives within a 20 min walk of a community pharmacy. 19 Distance has been identified as a significant factor of perceived access difficulties to GPs. 20 Participation by all community pharmacies therefore had the potential to improve access to influenza vaccination for more patients.
PharmOutcomes provided real-time information on vaccination activity, detailed reports on risk groups being vaccinated and sent messages directly to pharmacists. Majority of the notifications sent from PharmOutcomes were received and inputted into the patient records and uploaded into ImmForm. Significant data loss between the pharmacy and primary care systems has been reported 14 but was not the case in our study. PharmOutcomes allowed for notifications to be sent instantly, subject to the availability of a secure email address, and for reminders to be sent to pharmacists if notification was delayed. The information still needed to be inputted manually in the GP system. Having two separate information systems without a clear agreement and arrangements for activity to be transferred in to ImmForm could lead to data loss, especially if there is no close monitoring of timely notifications as is likely to be the case in a nationally commissioned service. In the absence of complete vaccination data, establishing the impact of pharmacy vaccination provision on uptake rates will be compromised.
A significant amount of project team time and resource was required to monitor the service and to ensure the service delivery was compliant with the SLA, data transfer was complete, complaints were dealt with, and providers and stakeholders were kept informed of progress. With a national programme, clarity on monitoring responsibilities between national and local teams will be required.
Although 37% of all active pharmacies were large chain pharmacies, they delivered 45% of all the vaccines. A range of factors could contribute to this, e.g. location in high streets and shopping malls resulting in high footfall, and more established set ups due to private provisions in the past. A voluntary sign up of pharmacies in a national programme, without consideration of need and distribution, may therefore result in inequities of access.
Our study thus identified areas for consideration to make improvements in the Structure and Process adopted for delivering the service, which can support the outcome of minimal data loss and facilitate better working relationships between primary care and pharmacists.
Limitations of the study
The study is based on the one year provision of a flu vaccination service. Primary care complaints and opinions were reactive, from a few practices and not based on a systematic survey. The study did not evaluate in detail the provider arrangements for delivering the service. The sample size for the audit was small. At 34%, the pharmacy survey response rate was low and findings may not be representative of the wider pharmacist views. This might be due to a number of factors, e.g. many pharmacies were part of large chains so did not report as individuals, there were multiple contacts with pharmacies through the process so they might have felt their views had been heard or they were generally happy with how the service had run and had felt no need to reply.
Conclusions
Our study found that the positive impact of community pharmacies was an increase in patient choice and convenience but no increase in uptake rates. Clear arrangements on activity transfer from pharmacists and inputting into GP systems, partnership working between GPs and Pharmacists and a communications strategy to increase awareness are essential for a successful service, even in a national process. The learning from this evaluation will be relevant for setting up any public health service with community pharmacies.
